BioLife Solutions, Inc. (BLFS) Reached 1-Year High at $8.93

May 16, 2018 - By Jason Dias

BioLife Solutions, Inc. (NASDAQ:BLFS) Corporate Logo

Big Money Sentiment decreased to 2.83 in 2017 Q4. It has change of 5.17, from 2017Q3’s 8. The ratio dropped due to BioLife Solutions, Inc. positioning: 2 sold and 4 reduced. 8 funds acquired positions and 9 increased positions. Investors holded 1.98 million in 2017Q3 but now own 1.37 million shares or 30.77% less.
Royal National Bank Of Canada reported 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Pennsylvania-based Hudock Capital Group Incorporated Limited Liability has invested 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Deutsche Comml Bank Ag owns 37,600 shs. Pnc Fincl Group holds 10,000 shs. First Manhattan reported 12,000 shs or 0% of all its holdings. Salem Invest Counselors, North Carolina-based fund reported 72 shs. Janney Montgomery Scott Lc reported 20,500 shs. Renaissance Technology Limited Liability holds 37,599 shs. Vanguard Inc invested 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Morgan Stanley has 215 shs for 0% of their capital. C M Bidwell & Assoc invested 0.03% in BioLife Solutions, Inc. (NASDAQ:BLFS). Essex Investment Management Limited Liability owns 254,096 shs. Eam Investors Ltd Liability Company has 97,077 shs. Macquarie Grp Inc Incorporated has 5,600 shs for 0% of their capital. Manatuck Hill Ptnrs Limited Com holds 0.16% or 50,000 shs.

BioLife Solutions, Inc. had 5 selling transactions and 0 insider purchases since January 16, 2018. This’s net activity of $5.68 million. On Thursday, February 15 12,540 shs were sold by Rice Michael, worth $65,960.

BioLife Solutions, Inc. (NASDAQ:BLFS) broke into yearly high touching $8.93. Our PT is $9.29. The yearly high was published on May, 16 by Barchart.com. It has $134.87M MC. The company’s valuation will be $5.39M more at $9.29 PT.

BLFS reached $8.93 during the last trading session after $0.03 change.BioLife Solutions, Inc. has volume of 91,746 shares. Since May 16, 2017 BLFS has risen 143.54% and is uptrending. BLFS outperformed the S&P 500 by 131.99%.

BioLife Solutions, Inc. (NASDAQ:BLFS)’s earnings report is anticipated by WallStreet on August, 9, as reported by RTT. Analysts forecast $-0.02 EPS. That’s $0.04 up or 66.67 % from 2017’s earnings of $-0.06. 100.00 % negative EPS growth is what analysts predict. $-0.01 EPS was announced for previous quarter.

BioLife Solutions, Inc. (NASDAQ:BLFS) Ratings Coverage

Total analysts of 2 have positions in BioLife Solutions (NASDAQ:BLFS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $12 highest while $7.5 is the lowest target price. The average target $9.75 is 9.18% above the last ($8.93) price. Since November 30, 2017 according to StockzIntelligence Inc BioLife Solutions has 3 analyst reports. On Monday, March 12 the rating was initiated by Northland Capital with “Buy”. On Friday, May 11 the firm has “Buy” rating given by Maxim Group. On Thursday, November 30 the firm earned “Buy” rating by Maxim Group.

A couple more BioLife Solutions, Inc. (NASDAQ:BLFS) news were brought out by: Benzinga.com which released on May 10, 2018 “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …”, also Nasdaq.com on April 26, 2018 brought out “Detailed Research: Economic Perspectives on Natural Health Trends, BioLife Solutions, The Chefs’ Warehouse …”, the next Prnewswire.com is “BioLife Solutions Makes Investment in SAVSU Technologies to Support Growth and Capture Additional Regenerative …” on May 16, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again”.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States.The firm is valued at $134.87 million. The Company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death.Last it reported negative earnings. The firm offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing.

BioLife Solutions, Inc. (NASDAQ:BLFS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.